A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients with MAPK Pathway-driven Advanced Solid Tumors with a Documented RAS, NF1, or RAF Mutation or Patients who have Failed BRAF/MEK Inhibition

2024-510900-34-00 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 22 Nov 2024 · Status Ongoing, recruiting · 2 EU/EEA countries · 3 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 36
Countries 2
Sites 3

Solid Tumors

Key facts

Sponsor
Pasithea Therapeutics Corp.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
22 Nov 2024 → ongoing
Decision date (initial)
2024-06-24
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Solid Tumors

VersionLevelCodeTermSystem organ class
20.0 LLT 10025648 Malignant mast cell tumors unspecified site extranodal and solid organ sites 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pasithea Therapeutics Corp.

Sponsor organisation
Pasithea Therapeutics Corp.
Address
1111 Lincoln Road Suite 500
City
Miami Beach
Postcode
33139-2439
Country
United States

Scientific contact point

Organisation
Pasithea Therapeutics Corp.
Contact name
Tiago Reis Marques

Public contact point

Organisation
Pasithea Therapeutics Corp.
Contact name
Tiago Reis Marques

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ongoing, recruiting 8 1
Romania Ongoing, recruiting 16 2
Rest of world
United States
12

Investigational sites

Bulgaria

1 site · Ongoing, recruiting
Multiprofile Hospital for Active Treatment Sveta Sofia
Oncology, Bulevard Bilgariya 104, 1404, Sofiya

Romania

2 sites · Ongoing, recruiting
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti
Medical Oncology II, Radiotherapy I, Soseaua Fundeni 252, 022328, Bucharest
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
Radiotherapy, Strada Republicii 34-36, 400015, Cluj-Napoca

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2025-01-08 2025-01-08
Romania 2024-11-22 2024-11-22

Application history

10 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-27 Romania Acceptable
2024-06-17
2024-06-24
2 SUBSTANTIAL MODIFICATION SM-1 2024-08-28 Romania Acceptable
2024-10-14
2024-10-21
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-12-12 Romania Acceptable
2024-06-17
2024-12-12
4 NON SUBSTANTIAL MODIFICATION NSM-3 2025-01-16 Romania Acceptable
2024-06-17
2025-01-16
5 NON SUBSTANTIAL MODIFICATION NSM-4 2025-03-06 Romania Acceptable
2024-06-17
2025-03-06
6 SUBSTANTIAL MODIFICATION SM-2 2025-04-04 Romania No conclusion
2025-06-11
2025-06-13
7 NON SUBSTANTIAL MODIFICATION NSM-5 2025-08-20 Romania No conclusion
2025-06-11
2025-08-20
8 NON SUBSTANTIAL MODIFICATION NSM-6 2025-12-05 No conclusion
2025-06-11
2025-12-05
9 NON SUBSTANTIAL MODIFICATION NSM-7 2026-01-12 Romania No conclusion
2025-06-11
2026-01-12
10 NON SUBSTANTIAL MODIFICATION NSM-8 2026-03-05 Romania No conclusion
2025-06-11
2026-03-05